Crestline Management LP Boosts Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Crestline Management LP grew its position in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 283.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 95,428 shares of the company's stock after purchasing an additional 70,571 shares during the period. Crestline Management LP owned approximately 0.11% of IDEAYA Biosciences worth $2,452,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of IDYA. Rhumbline Advisers grew its stake in shares of IDEAYA Biosciences by 0.5% in the fourth quarter. Rhumbline Advisers now owns 113,561 shares of the company's stock worth $2,919,000 after acquiring an additional 585 shares in the last quarter. Daiwa Securities Group Inc. boosted its holdings in IDEAYA Biosciences by 44.0% in the fourth quarter. Daiwa Securities Group Inc. now owns 2,792 shares of the company's stock valued at $72,000 after purchasing an additional 853 shares during the period. Mariner LLC grew its stake in IDEAYA Biosciences by 9.8% during the 4th quarter. Mariner LLC now owns 9,775 shares of the company's stock worth $251,000 after purchasing an additional 869 shares in the last quarter. Assetmark Inc. increased its holdings in IDEAYA Biosciences by 2.5% during the 4th quarter. Assetmark Inc. now owns 45,269 shares of the company's stock worth $1,163,000 after purchasing an additional 1,084 shares during the period. Finally, R Squared Ltd acquired a new stake in IDEAYA Biosciences in the 4th quarter valued at about $35,000. 98.29% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Stephens restated an "overweight" rating and set a $50.00 target price on shares of IDEAYA Biosciences in a research note on Friday, February 14th. Royal Bank of Canada reissued an "outperform" rating and issued a $61.00 price objective on shares of IDEAYA Biosciences in a research report on Wednesday, January 15th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of IDEAYA Biosciences in a research report on Monday, January 13th. Two analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $53.58.

IDEAYA Biosciences Stock Down 4.5 %

NASDAQ:IDYA traded down $0.81 during mid-day trading on Friday, reaching $17.37. 1,191,762 shares of the stock were exchanged, compared to its average volume of 990,259. IDEAYA Biosciences, Inc. has a 1 year low of $13.45 and a 1 year high of $44.42. The company has a 50 day simple moving average of $17.74 and a 200-day simple moving average of $22.64. The stock has a market capitalization of $1.52 billion, a P/E ratio of -5.26 and a beta of 0.26.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($0.82) EPS for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.07). During the same quarter last year, the business earned ($0.53) EPS. As a group, research analysts predict that IDEAYA Biosciences, Inc. will post -3.07 EPS for the current year.

About IDEAYA Biosciences

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.